- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01633372
An Open Label Study of Itacitinib Administered Orally in Patients With Myelofibrosis
August 25, 2021 updated by: Incyte Corporation
An Open-Label, Multiple Simon 2-Stage Study of Itacitinib Administered Orally to Subjects With Primary Myelofibrosis (PMF), Post Polycythemia Vera Myelofibrosis (PPV-MF) or Post Essential Thrombocythemia Myelofibrosis (PET-MF)
This is a study of itacitinib (INCB039110) in patients with myelofibrosis.
This study will evaluate safety and efficacy parameters of itacitinib (INCB039110).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
87
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New South Wales
-
Darlinghurst, New South Wales, Australia
- St Vincent's Hospital
-
Kogarah, New South Wales, Australia
- St. George Hospital
-
-
Victoria
-
Box Hill, Victoria, Australia
- Box Hill Hospital
-
Frankston, Victoria, Australia
- Frankston Hospital
-
-
-
-
Alberta
-
Edmonton, Alberta, Canada
- Cross Cancer Institute
-
-
British Columbia
-
Vancouver, British Columbia, Canada
- St. Paul's Hospital
-
-
Ontario
-
Toronto, Ontario, Canada
- Princess Margaret Hospital
-
-
Quebec
-
Montreal, Quebec, Canada
- St. Mary's Hospital
-
-
-
-
Alabama
-
Birmingham, Alabama, United States
- Birmingham Hematology Oncology Associates, LLC
-
-
Arizona
-
Scottsdale, Arizona, United States
- Mayo Clinic, Arizona
-
-
California
-
Los Angeles, California, United States
- UCLA Hematology & Oncology
-
-
Georgia
-
Atlanta, Georgia, United States
- Emory University
-
-
Maryland
-
Baltimore, Maryland, United States
- St Agnes Hospital
-
-
Michigan
-
Ann Arbor, Michigan, United States
- University of Michigan Cancer Center
-
-
New York
-
New York, New York, United States
- Mount Sinai School of Medicine
-
-
Oregon
-
Portland, Oregon, United States
- Oregon Health & Science University
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States
- University of Pennsylvania Health System
-
Pittsburgh, Pennsylvania, United States
- Western Pennsylvania Hospital
-
-
South Carolina
-
Columbia, South Carolina, United States
- South Carolina Oncology & Associates
-
-
Tennessee
-
Memphis, Tennessee, United States
- Boston Baskin Cancer Foundation, Inc.
-
Nashville, Tennessee, United States
- Tennessee Oncology
-
-
Texas
-
Houston, Texas, United States
- MD Anderson Cancer Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Must be diagnosed with PMF, PPV-MF or PET-MF as confirmed by bone marrow biopsy.
- Must score at least 1 point on the Dynamic International Prognostic Scoring System (DIPSS) for prognostic risk factors and have peripheral blast count <10% at both Screening and Baseline hematology assessments.
- Subjects must discontinue all drugs used to treat underlying MF disease no later than Day -14.
- Subjects must have hemoglobin value >/= 8.0g/dL and be willing to receive blood transfusions, have a platelet count >/=50x10^9/L and absolute neutrophil count (ANC) >/= 1x10^9/L.
- Subjects must have palpable spleen or history of splenectomy
- Active symptoms at the screening visit
Exclusion Criteria:
- Women who are pregnant or breastfeeding, and men and women who cannot comply with requirements to avoid fathering a child or becoming pregnant, respectively.
- Subjects with impaired liver function, end stage renal disease on dialysis or clinically significant concurrent infections requiring therapy.
- Subjects with unstable cardiac function or invasive malignancies over the previous 2 years except treated basal or squamous carcinomas of the skin, completely resected intraepithelial carcinoma of the cervix and completely resected papillary thyroid and follicular thyroid cancers.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: itacitinib 100 mg
itacitinib 100 mg twice a day
|
Other Names:
|
EXPERIMENTAL: itacitinib 200 mg
itacitinib 200 mg twice a day
|
Other Names:
|
EXPERIMENTAL: itacitinib 300 mg
itacitinib 300 mg once a day
|
Other Names:
|
EXPERIMENTAL: itacitinib 400 mg
itacitinib 400 mg once a day
|
Other Names:
|
EXPERIMENTAL: itacitinib 600 mg
itacitinib 600 mg once a day
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Proportion of subjects with >/= 50% reduction in total symptom score in each dose group, as measured by the modified The Myelofibrosis Symptom Assessment Form (MFSAF) v3.0 diary
Time Frame: Baseline and Week 12
|
Baseline and Week 12
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Proportion of subjects with >/= 35% reduction in spleen volume, and mean percent change in spleen volume
Time Frame: Baseline, Week 12 and Week 24
|
Baseline, Week 12 and Week 24
|
Proportion of transfusion dependent subjects who exhibit changes in transfusion frequency over any 12 week period on study and proportion of transfusion independent subjects who exhibit changes in hemoglobin level
Time Frame: Baseline to Week 12; Week 13 to Week 24 through the end of study or study termination visit.
|
Baseline to Week 12; Week 13 to Week 24 through the end of study or study termination visit.
|
Safety and tolerability of itacitinib as measured by adverse events.
Time Frame: Every 4-6 weeks through the end of study or early termination visit (approximately 33 weeks exclusive of the extension phase).
|
Every 4-6 weeks through the end of study or early termination visit (approximately 33 weeks exclusive of the extension phase).
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
July 16, 2012
Primary Completion (ACTUAL)
December 31, 2013
Study Completion (ACTUAL)
June 29, 2021
Study Registration Dates
First Submitted
June 26, 2012
First Submitted That Met QC Criteria
June 29, 2012
First Posted (ESTIMATE)
July 4, 2012
Study Record Updates
Last Update Posted (ACTUAL)
August 30, 2021
Last Update Submitted That Met QC Criteria
August 25, 2021
Last Verified
August 1, 2021
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- INCB 39110-230
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on MPN (Myeloproliferative Neoplasms)
-
Incyte CorporationCompletedMPN (Myeloproliferative Neoplasms)United States
-
Chengdu Zenitar Biomedical Technology Co., LtdRecruitingMyeloproliferative Neoplasm (MPN) | Myelofibrosis,MFChina
-
Incyte CorporationActive, not recruitingMPN (Myeloproliferative Neoplasms)United States, France, United Kingdom, Spain, Canada, Japan, Germany, Switzerland, Belgium, Austria, Italy
-
Chengdu Zenitar Biomedical Technology Co., LtdNot yet recruitingMyeloproliferative Neoplasm (MPN) | Myelofibrosis,MF
-
Incyte CorporationCompletedMPN (Myeloproliferative Neoplasms)United States, Netherlands, Austria
-
CelgeneCompletedPrimary Myelofibrosis | MPN-associated MyelofibrosisUnited States, Netherlands, France, Australia, Italy, United Kingdom, Canada, Germany, China, Spain, Belgium, Austria, Poland, Sweden, Japan, Russian Federation
-
Incyte CorporationCompletedMPN (Myeloproliferative Neoplasms)United States, Canada, Australia
-
Memorial Sloan Kettering Cancer CenterCompletedLymphoma | Metastatic Solid Tumor | Myeloproliferative Neoplasms (MPN)United States
-
Samus Therapeutics, Inc.WithdrawnAccelerated Phase MPN | Blast Phase MPN
-
Incyte CorporationCompletedProspective Observational Study Of Patients With Polycythemia Vera In US Clinical Practices (REVEAL)MPN (Myeloproliferative Neoplasms)United States, Puerto Rico
Clinical Trials on itacitinib
-
Incyte CorporationCompletedRheumatoid ArthritisUnited States, Puerto Rico
-
Incyte CorporationActive, not recruitingB-cell MalignanciesUnited States
-
Assistance Publique - Hôpitaux de ParisRecruitingSystemic SclerosisFrance
-
Incyte CorporationTerminatedBronchiolitis Obliterans SyndromeUnited States, Belgium, Canada
-
Incyte CorporationCompletedPolycythemia Vera | Myelofibrosis | ThrombocythemiaSpain, United States, Germany, Austria, Belgium, Italy, Poland
-
Imperial College LondonIncyte Biosciences UK LtdActive, not recruitingAdvanced Hepatocellular CarcinomaUnited Kingdom
-
Incyte CorporationAvailableSTAT1 Gain-of-Function Disease
-
John LevineCompletedGVHD | Low Risk Acute Graft-versus-host Disease | Graft-versus-host-diseaseUnited States
-
Columbia UniversityIncyte CorporationTerminatedGraft Vs Host Disease | Steroid Refractory GVHDUnited States
-
Incyte CorporationActive, not recruitingChronic Graft Versus Host Disease | Myelofibrosis | Postlung Transplant (Bronchiolitis Obliterans)United States, Spain, Italy, Germany, Belgium, Austria, Israel, Canada, Greece